TEL AVIV, Israel
September 27, 2012
Trial Studied Performance Of MGuard™ Embolic Protection Stent (EPS) In 433 Patients Undergoing Emergency Treatment For Heart Attacks
InspireMD, Inc. (OTCBB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary MGuard™ embolic protection stent platform technology for use in patients with Acute Myocardial Infraction announced today that
Gregg W. Stone
, MD will present initial results of the 433-patient randomized MASTER trial on
October 24, 2012
at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in
InspireMD previously announced (on
) that the MASTER (
trial demonstrated a positive outcome in patients suffering heart attacks when compared to commercially-approved bare metal or drug-eluting stents.
Presentation of detailed findings by Dr. Stone, the study's Chairman, is scheduled for the Late Breaking Trials session in the main arena on
Wednesday October 24
under the title "A Prospective, Randomized Trial of PET Micronet Mesh-Covered Stent vs. Standard Stents in Patients with ST-Segment Elevation Myocardial Infarction."
"The TCT conference is one of the world's premier events for new data and developments in interventional cardiology", said
, InspireMD's vice president of sales and marketing. "We are honored that the committee found the MASTER trial important enough for inclusion in the prestigious Late Breaking Clinical Trials session. We are hopeful this will broaden clinical awareness and adoption of our MGuard Embolic Protection Stent for the benefit of our customer physicians and their patients"
MASTER is the first Company-sponsored randomized clinical study comparing the MGuard™ Embolic Protection Stent to commercially-approved bare metal or drug-eluting stents in heart attack patients undergoing primary percutaneous coronary intervention (PPCI).